Dr Jolyon Martin, co-Founder and Head of Business Development at animal health start-up, PetMedix Ltd, has been named in the Forbes 30 under 30 Europe List for Science and Healthcare 2021. The honour recognises his ground-breaking work, translating cutting-edge human health technology into companion animals to provide precision treatments for pets. He has also been instrumental in the rapid growth of PetMedix towards becoming a significant player in the animal health market.
Forbes Magazine’s prestigious lists recognise 300 individuals across 10 categories under the age of 30 who have achieved excellence in their field. Nominees are judged on leadership and disruption; entrepreneurial mind-set and results; and the likelihood of changing their field over the next half-century. Dr Martin is the only honouree from an animal health company to be named in this year’s list.
During his PhD at the University of Cambridge, Dr Martin developed a transgenic mouse platform – a technology has resulted in a number of successful, novel therapies for humans – that is able to create fully canine antibodies. PetMedix is the only company in the world that has brought this innovative approach to veterinary medicine. The platform saves time and money in drug development, and reduces the risk of certain key adverse events relative to other antibody technologies. Development of a feline platform to develop treatments for cats is also underway.
Dr Martin says, “I am honoured to be included in the Forbes 30 under 30 list, and excited to join the global network of fellow entrepreneurs. I’ve always had a passion for animals, having been surrounded by dogs growing up. We also have increasing evidence about the close links between the health and welfare of pets and their human owners. I am thrilled that my work at PetMedix, developing therapeutics to fill a yawning gap in the provision of precision medicine for pets, has been recognised among such outstanding fellow honourees.“
Dr Martin will join fellow honourees as a member of the Forbes’ global Under 30 community, which comprises over 10,000 connected gamechangers worldwide.
Hetty Mulhall MA, Companion Consultancy
PetMedix™ is a Cambridge, UK based research and development stage biopharmaceutical company developing antibody-based therapeutics for companion animals. The growing team of more than 30 scientists have a great depth of experience building platforms that can develop species-specific therapeutic antibodies, and using them to bring novel therapies to market.
Driven by the core value of improving the health and welfare of animals, PetMedix™ is taking the cutting edge of human medicine and using it to develop innovative new veterinary treatments against a wide range of clinical indications for dogs and for cats.
Twitter: @PetMedix, LinkedIn: PetMedix,
Facebook: @PetMedix, Instagram: @PetMedix